Bluebird's gene therapy pricing: value, shared risk, lifetime cap - STAT

Bluebird's gene therapy pricing: value, shared risk, lifetime cap - STAT

Opinion: In pricing our gene therapy, Bluebird weighed value, shared risk, and a lifetime cap

By NICK LESCHLY

ADOBE

Bluebird Bio's pricing calculations for its new gene therapy considered a fair value, sharing the risk, and capping the total lifetime cost per patient.

READ MORE